Establishment of a biological bank of subjects vaccinated against SARS-Cov-2 infection(COVID-BioVac)
The purpose of the COVID-BioVac study is to establish a biobank of biological samples
from subjects who have received the anti-SARS-CoV-2 vaccine, with the ultimate aim
(following approval by the EC of specific substudies) to study and characterize the
antiviral immune response generated following anti-SARS-CoV-2 vaccination. To this end,
the COVID-BioVac Biobank will be officially established for the collection and storage of
human biological material, non-profit, to support research activities aimed at advancing
scientific knowledge, including in the genetic field, on the immune response.
vaccination-induced anti-SARS-CoV-2.
Other: biological bank
biological bank of subjects vaccinated against SARS-CoV-2 infection
Inclusion Criteria:
- Age ≥18 years
- Who have vaccinated for SARS-CoV-2 with Pfizer-BioNTech vaccine or others
- Signing of informed consent from January to March 2021
Exclusion Criteria:
- none
IRCCS Ospedale San Raffaele
Milan, Milano, Italy